Piper Jaffray has issued a report upgrading Gen-Probe GPRO from Neutral to Overweight.
According to the report, "Yesterday, the Wall Street Journal published an article describing Novartis' withdrawal from Gen-Probe takeover discussions, reportedly removing the last remaining bidder and causing GPRO shares to decline to levels well below when the initial story describing the company's potential sale broke on 4/28/11. Accordingly, we believe takeover speculation is largely out of the stock at current levels."
GPRO has a $78 Price Target and closed at $62.41 a share yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in